¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-3¿ù 31ÀÏ(1ÀÏÂ÷) : 2022-03-31

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-3¿ù 31ÀÏ(1ÀÏÂ÷) : 2022-03-31
±³À°ÀÏÀÚ : 2022-03-31
±³À°Àå¼Ò : ¿Â¶óÀΠ 
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-3¿ù 31ÀÏ(1ÀÏÂ÷) 
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
´ã´çÀÚ : Çѹ®¼÷
¿¬¶ôó : 02-566-6031  
À̸ÞÀÏ : icksh@icksh.org      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 55ºÐ  
¼¼ºÎ¼ö°­·á : 150,000¿ø      
ºñ°í 2¿ù 28ÀϱîÁö 100,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-31 Room 1 09:00~09:20 Next generation CAR-T cell therapy against hematological malignancies  ÃÖ°æÈ£(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 03-31 Room 1 09:20~09:40 Effective conditioning regimen in adoptive T cell therapy of cancer  ÇÑÁØ¿µ(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 03-31 Room 1 09:40~10:05 Tissue resident memory T cells in multiple myeloma  ÃÖÀ±¼÷(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 03-31 Room 1 10:05~10:30 T-cell-based immunotherapeutic strategies against EBV(Epstein-Barr virus)-positive malignancies using the novel TCR(T-Cell Receptor) specific for LMP1(latent membrane protein) antigen  ±èűÔ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03-31 Room 1 10:30~11:15 Immune landscape of hematological malignancies and functional screening tools  Satu Mustjoki(University of Helsinki Finland) 
±³À°½Ã°£ 03-31 Room 1 11:30~12:10 What is the role of C5 inhibitors in PNH(Paroxysmal nocturnal hemoglobinuria)?  ±èÁø¼®(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 03-31 Room 2 12:40~13:40 Potential prognostic significance of promoter methylation status of DNA repair genes at diagnosis in Acute myeloid leukemia: analysis of TCGA(Acute Myeloid Leukemia)-LAML(acute myeloid leukemia) cohort and patients in a single institution  ¹Ú¼³Èñ(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 03-31 Room 2 13:55~14:25 Recent advances in molecular diagnosis, prognosis and monitoring of MPNs(myeloproliferative neoplasm)  ±è¸í½Å(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03-31 Room 2 14:25~14:55 Molecular mechanisms underlying the development of MPN(myeloproliferative neoplasm) by mutant calreticulin and the therapeutic potential of an antibody targeting mutant calreticulin  Norio Komatsu(Juntendo University Japan) 
±³À°½Ã°£ 03-31 Room 2 14:55~15:25 Modeling improved targeting of JAK2V617F in MPNs(myeloproliferative neoplasm)  Andrew J. Dunbar(Memorial Sloan Kettering Cancer Center USA) 
±³À°½Ã°£ 03-31 Room 3 15:40~16:10 Immune landscapes and chemotherapy resistance in AML(cute myeloid leukemia)  Sergio Rutella(Nottingham Trent University UK) 
±³À°½Ã°£ 03-31 Room 3 16:10~16:40 Towards next-generation T cell engineering for cancer  ±èÂùÇõ(KAIST) 
±³À°½Ã°£ 03-31 Room 3 16:40~17:10 Endogenous retroviruses as a source of tumor antigens in solid tumors and acute myeloid leukemia  Stéphane Depil(Université Claude Bernard Lyon France) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-3¿ù 31ÀÏ(1ÀÏÂ÷) : 2022-03-31""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-4¿ù 1ÀÏ(2ÀÏÂ÷) : 2022-04-01
´ÙÀ½±Û (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2022-03-30
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20679 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦2Â÷¿¬¼ö±³À°(Ç÷°üÁúȯ, À̽ļö¼ú) : 2024-06-13 0 17 2024-05-10
20678 ¼­¿ï ±¸·Î±¸ÀÇ»çȸ 2024³âµµ Á¦2Â÷ ¿¬¼ö±³À° : 2024-06-11 0 20 2024-05-10
20677 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-06-10 0 24 2024-05-10
20676 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼ÒÈ­±â³»°ú ºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2024-06-09 0 25 2024-05-10
20675 Ãæ³² 2024³â »ó¹Ý±â ´ëÇÑÁßȯÀÚÀÇÇÐȸ ´ëÀü¼¼Á¾ÃæûÁöȸ ¿¬¼ö±³À° : 2024-06-08 0 10 2024-05-10
20674 ºÎ»ê 2024³â Á¦ 7ȸ ´ëÇÑÁßȯÀÚÀÇÇÐȸ ºÎ¿ï°æÁöȸ ¿¬¼ö°­Á : 2024-06-08 0 9 2024-05-10
20673 ´ë±¸ Á¦24Â÷ ´ë±¸°æºÏ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­Á : 2024-06-08 0 16 2024-05-10
20672 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 1Â÷ : 2024-06-08 0 9 2024-05-10
20671 ¼­¿ï »ï¼º¼­¿ïº´¿ø ÈäºÎ¿Ü°ú SMC MCS Symposium 2024 : 2024-06-08 0 11 2024-05-10
20670 ¼­¿ï 2024 ´ëÇѵðÁöÅÐÀÓ»óÀÇÇÐȸ ÇÏ°è Çмú´ëȸ : 2024-06-02 0 8 2024-05-10
20669 ¼­¿ï Á¦6ȸ ´ëÇѼö¼úÁ߽Űæ°è°¨½ÃÇÐȸ ¿¬¼ö°­Á : 2024-06-01 0 7 2024-05-10
20668 ºÎ»ê ±¸Á¶½ÉÁúȯ¿¬±¸È¸ The 7th K-SCI(Korea Structural Cardiovascular Intervention) Symposium : 2024-06-01 0 8 2024-05-10
20667 ±¤ÁÖ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ 2024³â ÇÁ·ÎÆ÷Æú ÁøÁ¤±³À° : 2024-06-01 0 9 2024-05-10
20666 ´ëÀü 2024³â ´ëÇÑ°¡Á¤ÀÇÇÐȸ ´ëÀü¼¼Á¾Áöȸ Ãá°èÇмú´ëȸ(°íÇ÷¾Ð, °ú¹Î¼º ÀåÁõÈıº, ¼ö¸éÀå¾Ö) : 2024-05-30 0 12 2024-05-10
20665 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø ºñ´¢ÀÇÇаú ¿¬¼ö°­Á : 2024-05-30 0 26 2024-05-10
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷